Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYile ZhouSun Yat-sen UniversityLMLiping MaoLiaoning UniversityHTHongyan TongZhejiang Cancer Hospital

Discussion

Loading...

Member takes

Implication

Retrospective study compares treatment efficacy of short-course blinatumomab in relapsed B-ALL patients, highlighting impact on survival outcomes.

Key Points

  • To compare the efficacy of short-course versus standard-course blinatumomab in patients with B-cell acute lymphoblastic leukemia.
  • Multicenter retrospective study conducted from March 2022 to July 2025
  • Patients with B-ALL were treated with blinatumomab and divided into two cohorts based on treatment duration
  • Outcomes assessed include complete remission rate, MRD-negative rate, overall survival, and progression-free survival.
  • No significant differences in CR/CRi rates between short-course and standard-course treatments
  • MRD-negative rates were similar in both cohorts, particularly in patients with low leukemia burden
  • Infection rates were higher in the standard-course group, implying treatment duration may impact toxicity.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de67https://doi.org/10.1182/blood-2025-1562
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Infusion of 14 days Blinatumomab in Combination with Chemotherapy for 46-day MRD+ Pediatric B-ALL Patients in Intermediate/High-Risk Group Results in MRD Conversion and BiTE Induced Immune Response to Malignant Cells2024
  3. 3Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance2026
  4. 4Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL2026 · 2 citations
  5. 5Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026